Alpha Cognition (ACOG) Stock Analysis & Winston Score
Alpha Cognition is a small pharmaceutical company focused on treatments for Alzheimer's disease. Its main product is ZUNVEYL, an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate Alzheimer's. The company sells to patients and caregivers through pharmacies and healthcare providers in the United States. Alpha Cognition earns revenue by selling ZUNVEYL directly into the U.S. prescription drug market. It is a very small company with a market cap around $100 million, and it currently spends far more money than it brings in, as shown by its deeply negative operating margin. The company has no wide competitive moat — it competes against established Alzheimer's drugs from much larger pharmaceutical companies — and its biggest risk is whether it can grow prescription volume fast enough to reach profitability before running out of cash.
Winston Score: 27/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (10/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $8.50
Market Cap: $132M
Sector: Financial Services
Industry: Financial - Conglomerates
Exchange: NASDAQ
